BRPI0408167A - conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais - Google Patents

conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais

Info

Publication number
BRPI0408167A
BRPI0408167A BRPI0408167-6A BRPI0408167A BRPI0408167A BR PI0408167 A BRPI0408167 A BR PI0408167A BR PI0408167 A BRPI0408167 A BR PI0408167A BR PI0408167 A BRPI0408167 A BR PI0408167A
Authority
BR
Brazil
Prior art keywords
polysaccharide
protein
immunization against
staphylococcal surface
nosocomial infections
Prior art date
Application number
BRPI0408167-6A
Other languages
English (en)
Inventor
Viliam Pavliak
Steven Morris Baker
Subramonia Padmanaba Pillai
Joseph M Patti
Bradley D Prater
Original Assignee
Wyeth Corp
Inhibitex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Inhibitex Inc filed Critical Wyeth Corp
Publication of BRPI0408167A publication Critical patent/BRPI0408167A/pt
Publication of BRPI0408167B1 publication Critical patent/BRPI0408167B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"CONJUGADOS DE POLISSACARìDEO-PROTEìNA VEìCULO ADESINA DA SUPERFìCIE ESTAFILOCóCICA PARA IMUNIZAçãO CONTRA INFECçõES NOSOCOMIAIS". A presente invenção refere-se a conjugados imunogênicos de polissacarídeo-proteína tendo um antígeno de polissacarídeo (ou seu fragmento de oligossacarídeo representando um ou mais epitopos antigênicos) derivado de um agente patogênico nosocomial conjugado a uma proteína veículo adesina da superfície estafilocócica que são usados em composições imunogênicas para estimular respostas de anticorpo ao antígeno de polissacarídeo e à proteína veículo adesão da superfície estafilocócica. Tais composições imunogênicas são usadas para imunizar contra doenças causadas por Staphylococcus aureus, Staphylococcus epidermidis ou outros agentes patogênicos nosocomiais.
BRPI0408167-6B1A 2003-03-07 2004-03-04 Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais BRPI0408167B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45272803P 2003-03-07 2003-03-07
US60/452,728 2003-03-07
PCT/US2004/006661 WO2004080490A2 (en) 2003-03-07 2004-03-04 Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections

Publications (2)

Publication Number Publication Date
BRPI0408167A true BRPI0408167A (pt) 2006-03-21
BRPI0408167B1 BRPI0408167B1 (pt) 2014-10-21

Family

ID=32990675

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408167-6B1A BRPI0408167B1 (pt) 2003-03-07 2004-03-04 Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais

Country Status (12)

Country Link
US (2) US9296795B2 (pt)
EP (1) EP1601381A2 (pt)
JP (2) JP5102487B2 (pt)
KR (1) KR20060035581A (pt)
CN (2) CN1787839B (pt)
AU (1) AU2004220590B2 (pt)
BR (1) BRPI0408167B1 (pt)
CA (1) CA2517439C (pt)
MX (1) MXPA05009351A (pt)
NZ (1) NZ561879A (pt)
WO (1) WO2004080490A2 (pt)
ZA (1) ZA200508086B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565478B1 (en) 2002-11-12 2017-08-02 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
JP4764830B2 (ja) * 2003-12-17 2011-09-07 ワイス・エルエルシー 免疫原性ペプチド担体コンジュゲートおよびその生産法
EP2460813A1 (en) * 2003-12-17 2012-06-06 Janssen Alzheimer Immunotherapy A beta immunogenic peptide carrier conjugates and methods of producing same
EP1804833A2 (en) * 2004-09-22 2007-07-11 GlaxoSmithKline Biologicals SA Staphylococcal immunogenic compositions
FR2884830A1 (fr) 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
GB0526038D0 (en) * 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
EP2476433A1 (en) * 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogenic composition
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
PE20120262A1 (es) * 2006-03-30 2012-03-30 Glaxosmithkline Biolog Sa Procedimiento para la preparacion de inmunoconjugados que comprenden polisacarido u oligosacarido capsular de s. aureus junto con la proteina portadora
FR2899110A1 (fr) 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
KR100829257B1 (ko) * 2006-06-22 2008-05-14 부경대학교 산학협력단 인간 섬유육종세포에서 메트릭스 메탈로프로테이나제-9의발현 및 활성을 억제하는 카복시화 글루코사민 화합물 및이를 함유한 메트릭스 메탈로프로테이나제-9 억제제
KR100780868B1 (ko) 2006-07-10 2007-11-30 부경대학교 산학협력단 항암효과를 나타내는 4급 아미노 글루코사민 화합물
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EP2666784B1 (en) * 2007-08-31 2017-04-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2009127677A1 (en) * 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
DK2315747T3 (en) 2008-07-21 2018-02-26 Brigham & Womens Hospital Inc Methods and Compositions of Synthetic Beta-1.6 Glucosamine Oligosaccharides
US9125951B2 (en) * 2009-06-22 2015-09-08 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
NZ616921A (en) 2009-07-15 2015-06-26 Genentech Inc Gram-positive bacteria specific binding compounds
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013506651A (ja) 2009-09-30 2013-02-28 ノバルティス アーゲー Staphylococcus.aureus5型および8型莢膜多糖の結合体
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8
CA2819120C (en) 2010-12-22 2016-07-05 Wyeth Llc Stable immunogenic compositions of staphylococcus aureus antigens
CN102759618A (zh) * 2012-07-18 2012-10-31 成都欧林生物科技股份有限公司 用ELISA法检测血清中Hib多糖抗体含量的方法
MX363511B (es) 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
HRP20221438T1 (hr) 2012-12-20 2023-02-03 Pfizer Inc. Postupak glikokonjugiranja
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
DK3010535T3 (da) * 2013-06-19 2020-11-30 Integrated Biotherapeutics Inc Toxoide peptider afledt fra fenol opløselige modulin, delta toxin, superantigener og fusioner deraf
JP2016540764A (ja) * 2013-12-04 2016-12-28 グリコヴァキシン アーゲー 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防
US10668164B2 (en) 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
MX2017007652A (es) 2014-12-10 2017-10-11 Glaxosmithkline Biologicals Sa Metodo de tratamiento.
EP3292146A1 (en) 2015-05-04 2018-03-14 Pfizer Inc Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US11446371B2 (en) 2015-11-05 2022-09-20 The Texas A&M University System Targeting of ligand binding sites in ClfA
CN106084037B (zh) * 2016-06-08 2020-01-07 中国人民解放军第二军医大学 一种炭疽杆菌荚膜表面三糖缀合物及其制备方法和应用
CN106366163A (zh) * 2016-10-31 2017-02-01 中国人民解放军第二军医大学 一种β‑1,2‑D‑寡聚甘露糖肽‑蛋白缀合物及其制备方法和应用
TW201925222A (zh) * 2017-06-23 2019-07-01 美商醫院疫苗公司 免疫原性組成物
CA3069747A1 (en) 2017-07-27 2019-01-31 Mohammad Javad Aman Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
CN110484773B (zh) * 2019-09-12 2020-06-23 江苏沃钛有色金属有限公司 一种钛合金基材及其制备方法
JP2023526780A (ja) 2020-05-01 2023-06-23 神州細胞工程有限公司 タンパク質/ペプチド抗原の免疫原性を向上させる方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189015A (en) 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
US5571514A (en) 1987-06-01 1996-11-05 Alfa Laval Ab Fibronectin binding protein as well as its preparation
US5320951A (en) 1987-06-01 1994-06-14 Hoeoek Magnus Fibronectin binding protein as well as its preparation
SE8801894D0 (sv) 1988-05-20 1988-05-20 Alfa Laval Agri Int Fibronektinbindande protein
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US5440014A (en) 1990-08-10 1995-08-08 H+E,Uml/Oo/ K; Magnus Fibronectin binding peptide
US5851794A (en) 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
US5980908A (en) 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
US20020173462A1 (en) * 1992-09-21 2002-11-21 Boden Wastfelt Maria K. Fibrinogen binding protein
IL107458A0 (en) * 1992-11-02 1994-02-27 Gen Hospital Corp Conjugate vaccine against group b streptococcus
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
CA2255669A1 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
WO1999003871A1 (en) * 1997-07-17 1999-01-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hexadecasaccharide-protein conjugate vaccine for shigella dysenteriae type 1
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
WO2000012689A1 (en) 1998-08-31 2000-03-09 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
ATE422368T1 (de) * 1998-08-31 2009-02-15 Inhibitex Inc Multikomponenten impfstoffe gegen staphylococcus aureus
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
AU5408099A (en) 1998-09-01 2000-03-21 John F. Wetling Electrically treated composition and use thereof
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
EP1035137A1 (en) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
JP4846906B2 (ja) * 1999-03-19 2011-12-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2000071585A1 (en) * 1999-05-03 2000-11-30 Medarex, Inc. Human antibodies to staphylococcus aureus
DE19937864C2 (de) * 1999-08-13 2002-10-31 Rudolf Marx Werkstück und Verfahren zum Herstellen und zum Verwerten des Werkstückes
EP2298736B1 (en) * 2000-03-22 2015-07-15 Solulink, Inc. Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
GB0007432D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
MXPA03006561A (es) 2001-01-23 2004-10-15 Aventis Pasteur Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
EP2339344A1 (en) 2001-06-15 2011-06-29 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA2351018A1 (en) * 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
JP2005536185A (ja) 2002-03-05 2005-12-02 インヒビテックス インコーポレーテッド コアグラーゼ陰性ブドウ球菌タンパク質を認識するモノクローナルおよびポリクローナル抗体
NZ561879A (en) 2003-03-07 2009-05-31 Wyeth Corp Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)

Also Published As

Publication number Publication date
JP2012051922A (ja) 2012-03-15
AU2004220590A1 (en) 2004-09-23
CN102366630A (zh) 2012-03-07
JP5102487B2 (ja) 2012-12-19
MXPA05009351A (es) 2006-03-08
US20070087014A1 (en) 2007-04-19
CA2517439C (en) 2013-07-23
US20070141077A1 (en) 2007-06-21
KR20060035581A (ko) 2006-04-26
CN102366630B (zh) 2015-04-01
JP5757841B2 (ja) 2015-08-05
CA2517439A1 (en) 2004-09-23
WO2004080490A3 (en) 2004-10-28
US8377451B2 (en) 2013-02-19
EP1601381A2 (en) 2005-12-07
AU2004220590B2 (en) 2010-02-18
JP2006519870A (ja) 2006-08-31
CN1787839B (zh) 2011-09-28
CN1787839A (zh) 2006-06-14
NZ561879A (en) 2009-05-31
WO2004080490A2 (en) 2004-09-23
US9296795B2 (en) 2016-03-29
ZA200508086B (en) 2010-04-28
BRPI0408167B1 (pt) 2014-10-21

Similar Documents

Publication Publication Date Title
BRPI0408167A (pt) conjugados de polissacarìdeo-proteìna veìculo adesina da superfìcie estafilocócica para imunização contra infecções nosocomiais
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
BRPI0407101A (pt) Vacinas meningocócicas mucosais
MX2021015775A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos.
CL2010000397A1 (es) Composicion que provee inmunidad protectora contra micoplasma hyopneumoniae que comprende una cantidad inmunizante de dicha bacteria, al menos otro antigeno viral o bacteriano, un adyuvante y un vehiculo farmaceutico, util para lograr proteccion inmune en animales. (divisional de solicitud 2003-00957)
Péchiné et al. Targeting Clostridium difficile surface components to develop immunotherapeutic strategies against Clostridium difficile infection
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
KR920003982A (ko) 면역원성 콘쥬게이트 및 이를 함유하는 백신 조성물
BRPI0009163B8 (pt) composição imunogênica e vacina que a compreende
DE60230670D1 (de) Staphylococcus aureus exopolysaccharid und verfahren
PE20071058A1 (es) Vacuna de streptococcus pneumoniae
ATE198051T1 (de) Pneumokokken-polysaccharid-rekombinante- pneumolysin-konjugate als impfstoffe für die immunisierung gegen pneumokokken-infektionen
BR0207068A (pt) Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
CY1113020T1 (el) Εμβολια συνδυασμου για neisseria meningitidis
BRPI0612670B8 (pt) composição imunogênica, vacina a compreendendo e kit de vacina para a administração concomitante ou sequencial
Maira-Litran et al. Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A
BRPI0408085A (pt) composição e método para o tratamento e prevenção de infecções entéricas bacterianas
TW200716670A (en) Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
BRPI0410341B8 (pt) conjugados de polissacarídeo-proteína derivatizados de meningococos multivalentes e vacina
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
MA45283A1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela
BRPI0510659A (pt) indução de uma resposta imunológica contra polissacarìdeos de streptococcus pneumoniae
MX2023013434A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 47/48, 39/385; C07K 16/12; A61P 37/00, 37/04

Ipc: A61K 47/48 (2011.01), A61K 39/385 (2011.01), C07K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 47/48 , A61K 39/385 , C07K 16/12 , A61P 37/00 , A61P 37/04

Ipc: A61K 39/085 (2006.01), A61K 39/385 (2006.01), C07K

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/10/2014, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)